nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Although the term was coined in the late 1980s one of the first retroactively recognized examples of a killer application is the VisiCalc spreadsheet, released in 1979 for the Apple II. Because it was not released for other computers for 12 months, people spent US$100 (equivalent to $400 in 2025) for the software first, then $2,000 to $10,000 (equivalent to $9,000 to $44,000) on the requisite Apple II. Byte wrote in 1980, "VisiCalc is the first program available on a microcomputer that has been responsible for sales of entire systems", and Creative Computing's VisiCalc review is subtitled "reason enough for owning a computer". Others also chose to develop software, such as EasyWriter, for the Apple II first because of its higher sales, helping Apple defeat rivals Commodore International and Tandy Corporation. The co-creator of WordStar, Seymour Rubinstein, argued that the honor of the first killer app should go to that popular word processor, given that it came out a year before VisiCalc and that it gave a reason for people to buy a computer. However, whereas WordStar could be considered an incremental improvement (albeit a large one) over smart typewriters like the IBM Electronic Selectric Composer, VisiCalc, with its ability to instantly recalculate rows and columns, introduced an entirely new paradigm and capability unavailable on larger computers. Lotus 1-2-3 similarly benefited sales of the IBM PC. Noting that computer purchasers did not want PC compatibility as much as compatibility with certain PC software, InfoWorld suggested "let's tell it like it is.
== References == Aldose reductase inhibitor for treatment of diabetic complications. Prepn (stereo unspec): M. Kurono, et al., EP 193415; eidem, US 4740517 (1986, 1988 both to Sanwa) Prepn of isomers: T. Yamaguchi et al., Arzneim.-Forsch. 44, 344 (1994) Pharmacological profile: K. Mizuno et al. in Current Concepts of Aldose Reductase and Its Inhibitions, N. Sakamoto et al., Eds. (Elsevier, Amsterdam, 1990) pp 89–96. Configuration and crystal structure of complex with aldose reductase: M. Oka et al., J. Med. Chem. 43, 2479 (2000). Clinical efficacy in diabetic peripheral neuropathy: N. Hotta et al., Diabetes Care 24, 1776 (2001). Clinical suppression of sorbitol accumulation in erythrocytes of diabetic patients: T. Asano et al., J. Diabetes Complications 16, 133 (2002); eidem, ibid. 18, 336 (2004). Review of clinical development: N. Giannoukakis, Curr. Opin. Invest. Drugs 4, 1233-1239 (2003).
== PLP-enzymes == PLP is retained in the active site not only thanks to the lysine, but also thanks to the interaction of the phosphate group and a phosphate binding pocket and to a lesser extent thanks to base stacking of the pyridine ring with an overhanging aromatic residue, generally tyrosine (which may also partake in the acid–base catalysis). Despite the limited requirements for a PLP binding pocket, PLP enzymes belong to only five different families. These families do not correlate well with a particular type of reaction. The five families are classified as fold types followed by a Roman numeral.
CO2carbondioxide + 2H2Aelectron donor + photonslight energy → [CH2O]carbohydrate + 2Aoxidizedelectrondonor + H2Owater Since water is used as the electron donor in oxygenic photosynthesis, the equation for this process is:
Sources: en.wikipedia.org
The science of collecting and analyzing biologic or health data using statistical methods. Biostatistics may be used to help learn the possible causes of a disease in a certain group of people. Also called biometry and biometrics. (NCI) Blind
It was announced in March 2017 that Galloway was standing as an independent candidate at the Manchester Gorton by-election, following the death of Sir Gerald Kaufman. Gorton had been one of Labour's safest seats. The by-election was cancelled following the announcement of the 2017 snap general election being held on 8 June. Galloway transferred his candidacy to the general election. Labour easily retained the seat; Galloway came a distant third with 6% of the vote. In the 2019 general election, Galloway contested the Parliamentary seat of West Bromwich East as an independent, describing himself as supportive of Corbyn's leadership and Brexit. He came sixth with 489 votes. On 14 December 2019, Galloway launched the Workers Party of Britain, which describes itself as "economically radical with an independent foreign policy" and "unequivocally committed to class politics". Galloway is the party's leader. In 2020 Galloway announced his intention to stand in an expected by-election in Rutherglen and Hamilton West, after sitting MP Margaret Ferrier breached COVID regulations, but the by-election was not held for 3 years. Galloway led All for Unity in the 2021 Scottish Parliament election and announced his intention to vote for the Conservative Party on the constituency vote, and for his party on the list vote. This contradicted other occasions when he said voting Conservative was something he would never consider. All for Unity received 23,299 votes in the election, or 0.9%, placing the party 7th nationally, with no seats.
=== Bisulfite Treatment === Genomic DNA of interest is treated with sodium bisulfite, which introduces methylation-dependent sequence differences. During sodium bisulfite treatment, unmethylated cytosine residues are converted to uracil, while methylated cytosine residues are unaffected.
== External links == "Viral Haemorrhagic Fever". The National Archives of United Kingdom. Public Health England (PHE). Archived from the original on 2014-07-14. "Viral Haemorrhagic Fevers". World Health Organization (WHO). United Nations (UN). Archived from the original on August 23, 2004. "Viral Hemorrhagic Fevers (VHFs) Virus Families". National Center for Emerging and Zoonotic Infectious Diseases (NCEZID). U.S. Centers for Disease Control and Prevention (CDC). 2019-09-24.
Previously, UNAMA had reported that between 26 February and 16 March, at least 76 civilian were killed and 213 were injured in Afghanistan as result of armed clashes between Taliban forces and Pakistan armed forces. On the same day, Pakistani officials said that they had foiled an attempt by Taliban forces to attack a Pakistani border post in Khyber Pakhtunkhwa's Ghulam Khan Sector, killing 37 Taliban fighters and injuring 80 others. Furthermore, Pakistani officials stated that since the start of hostilities, 796 Afghan Taliban and TTP militants had been killed and more than 1,043 injured. They added that Pakistani forces had destroyed 286 check-posts, captured 44 others, destroyed 249 tanks, armored vehicles, and artillery guns, and targeted 81 locations across Afghanistan in air strikes. On 6 April, an Afghan media outlet, citing tribal elders and local residents, reported that Taliban forces had abandoned several border posts in Nuristan and Kunar following recent clashes with Pakistani forces. The abandoned positions were said to be located in the Bari Kot area of Nari district, as well as in parts of Bargi Matal and Kamdesh. According to the report, Taliban fighters who withdrew from the posts took shelter in village mosques. Some tribal elders from these area accuse the Taliban of failing to maintain security in the border areas and of spreading misinformation about their presence. They say that Taliban members travel by helicopter to district centres in order to create the impression that the group remains active in the region.
Sources: en.wikipedia.org
Neurapraxia is the least severe form of nerve injury, with complete recovery. In this case, the axon remains intact, but there is myelin damage causing an interruption in conduction of the impulse down the nerve fiber. Most commonly, this involves compression of the nerve or disruption to the blood supply (ischemia). There is a temporary loss of function which is reversible within hours to months of the injury (the average is 6–8 weeks). Wallerian degeneration does not occur, so recovery does not involve actual regeneration. There is frequently greater involvement of motor than sensory function with autonomic function being retained. In electrodiagnostic testing with nerve conduction studies, there is a normal compound motor action potential amplitude distal to the lesion at day 10, and this indicates a diagnosis of mild neurapraxia instead of axonotmesis or neurotmesis.
=== ARDS in COVID-19 === Studies have found that aviptadil may be beneficial for severely ill patients with COVID-19 related ARDS. ACTIV-3, a trial examining aviptadil acetate (Zyesami), is recruiting patients as of July 2, 2021. A separate trial is examining inhaled aviptadil for patients with high risk for ARDS, is ongoing as of May 21, 2021. A trial for intravenous aviptadil for the same indication concluded in February 2021. US-Israeli NeuroRx Inc partnered with Relief Therapeutics to develop aviptadil in the United States. In June 2020, the U.S. Food and Drug Administration granted fast-track designation to aviptadil for the treatment of respiratory distress in COVID-19. In September 2020, NeuroRX submitted a request for an Emergency Use Authorization to the US FDA for its use in patients in intensive care. Jan 2021: Zuventus healthcare Ltd seeks approval for aviptadil from India's drug controller for emergency use in COVID-19 treatment. Mumbai's Zuventus Healthcare Ltd. has got the nod to conduct Phase 3 clinical trials of aviptadil injectable formulation. The SEC noted that Zuventus had presented revised Phase 3 clinical trial protocol before the committee, and after "detailed deliberation", it recommended grant of permission of Phase 3 trials with the drug. May 2021: NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (aviptadil-acetate) and Submits Emergency Use Authorization Application to USFDA to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure.
=== Reconstitution in exile === In January 1921, Russian émigrés meeting in Warsaw re-established the organization under the name People's Union for the Defense of the Motherland and Freedom. The reconstituted organization sought to continue anti-Bolshevik activity from abroad and to rebuild an underground network inside Soviet territory. Between 1921 and 1923, the People's Union engaged in underground and subversive activities directed against the Bolshevik regime. Volunteers and operatives were sent into the Soviet Union in an effort to organize armed detachments, establish clandestine cells, recruit supporters, and attempt to provoke a broader anti-Bolshevik uprising.
March 11: Decree improving breastfeeding conditions in industrial and commercial establishments (dedicated rooms, breastfeeding facilities, cribs, and qualified staff). December 3: Decree enacting the International Convention for the Suppression of the Traffic in Women and Children (signed September 30, 1921); France adhered in January 1926 with reservations regarding colonies, protectorates, or mandates. December 7: Law amending Article 72 of Book II of the Labor and Social Welfare Code (list of jobs prohibited to children under 18 and to women). December 1: Maritime Labor Code; a married woman may not board a ship without her husband's permission—or court authorization. 1927
On 7 October 2023, a geopolitical conflict began between the State of Israel and Hamas in the Gaza Strip region, which significantly shook the international community. Brazil, at first, did not classify Hamas as a terrorist organization, since the country's policy on this issue directly agrees with the UN classification, which also did not classify it as a terrorist. On the same day, the Ministry of Foreign Affairs and the federal government organized a rescue operation for Brazilians who were in Israel, being the first country to do so. Days later, several planes belonging to the Brazilian Air Force were sent to the region of Israel in order to rescue Brazilians who wanted to go back to Brazil. On his social networks, President Lula made a post in which he condemned the Hamas attacks and described Brazil as capable of "finding a path to peace". Lula also published that he spoke to Israeli president Isaac Herzog and ratified his repudiation of the events, while also calling for Israel to take all measures to prevent a humanitarian crisis. He also later spoke with the Mahmoud Abbas, president of the Palestinian Authority, and Abdul Fatah Khalil Al-Sisi, president of Egypt. On 20 October, Lula spoke out again on social media, classifying the Hamas attack as an "act of madness" and "terrorism against Israel", and Israel's response as "insane", citing the high mortality rate (especially of children and infants) in Gaza during the bombings and invasion.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.